NCT06204679View on ClinicalTrials.gov

Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 14, 2023

Primary Completion Date

August 25, 2024

Study Completion Date

August 25, 2024

Conditions
Healthy Volunteer Study
Interventions
DRUG

Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions

A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)

DRUG

Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions

A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)

DRUG

Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions

Bemnifosbuvir (BEM) and Ruzasvir (RZR) as separate formulations

Trial Locations (1)

90630

Atea Study Site, Cypress

Sponsors
All Listed Sponsors
lead

Atea Pharmaceuticals, Inc.

INDUSTRY

NCT06204679 - Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir | Biotech Hunter | Biotech Hunter